Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer
- PMID: 17879946
- DOI: 10.1002/jcb.21552
Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer
Abstract
Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Two primary reasons explain its aggressive behavior: most patients present with advanced disease at diagnosis, and die of recurrences from disease that has become resistant to conventional chemotherapies. In this paper on epithelial ovarian cancer (EOC), we will review molecular alterations associated with the few precursor lesions identified to date, followed by the more commonly recognized processes of de novo carcinogenesis, metastasis, and the development of chemoresistance. We will propose a unifying model of ovarian epithelial tumorigenesis that takes into account various hypotheses. We will also review novel approaches to overcome the major problem of chemoresistance in ovarian cancer. Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance.
(c) 2007 Wiley-Liss, Inc.
Similar articles
-
Early events in ovarian oncogenesis.Reprod Biol Endocrinol. 2003 Oct 7;1:68. doi: 10.1186/1477-7827-1-68. Reprod Biol Endocrinol. 2003. PMID: 14577833 Free PMC article. Review.
-
Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses.Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21. doi: 10.1016/j.mce.2005.09.014. Epub 2005 Nov 16. Mol Cell Endocrinol. 2006. PMID: 16297528 Review.
-
Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis.Int Rev Cytol. 2005;242:1-54. doi: 10.1016/S0074-7696(04)42001-4. Int Rev Cytol. 2005. PMID: 15598466 Review.
-
Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.Gynecol Oncol. 2008 Feb;108(2):385-94. doi: 10.1016/j.ygyno.2007.10.035. Epub 2007 Nov 26. Gynecol Oncol. 2008. PMID: 18036641
-
Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer.Cancer Res. 2005 Apr 15;65(8):3025-9. doi: 10.1158/0008-5472.CAN-04-3931. Cancer Res. 2005. PMID: 15833827
Cited by
-
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.Br J Cancer. 2009 Mar 10;100(5):707-12. doi: 10.1038/sj.bjc.6604914. Epub 2009 Feb 17. Br J Cancer. 2009. PMID: 19223898 Free PMC article.
-
Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.Gynecol Oncol. 2009 Sep;114(3):480-5. doi: 10.1016/j.ygyno.2009.05.045. Epub 2009 Jun 27. Gynecol Oncol. 2009. PMID: 19560192 Free PMC article.
-
Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers.BMC Cell Biol. 2012 Oct 8;13:25. doi: 10.1186/1471-2121-13-25. BMC Cell Biol. 2012. PMID: 23039795 Free PMC article.
-
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.BMC Cancer. 2015 Jul 25;15:547. doi: 10.1186/s12885-015-1539-8. BMC Cancer. 2015. PMID: 26205780 Free PMC article.
-
The detection, treatment, and biology of epithelial ovarian cancer.J Ovarian Res. 2010 Mar 29;3:8. doi: 10.1186/1757-2215-3-8. J Ovarian Res. 2010. PMID: 20350313 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical